These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37963164)

  • 1. A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases.
    Kanankulam Velliangiri S; Ballal S; Prasad Yadhav M; Tripathi M; Satapathy S; Bal C
    PLoS One; 2023; 18(11):e0294343. PubMed ID: 37963164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Survival After Multimodal Approach with
    Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up.
    Qiu ZL; Shen CT; Sun ZK; Song HJ; Xi C; Zhang GQ; Wang Y; Luo QY
    Front Endocrinol (Lausanne); 2020; 11():588024. PubMed ID: 33716950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
    Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
    Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
    Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
    Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
    Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
    Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area.
    Mishra A; Mishra SK; Agarwal A; Das BK; Agarwal G; Gambhir S
    World J Surg; 2002 Feb; 26(2):153-7. PubMed ID: 11865341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.
    Slook O; Levy S; Slutzky-Shraga I; Tsvetov G; Robenshtok E; Shimon I; Benbassat C; Hirsch D
    Endocr Pract; 2019 May; 25(5):427-437. PubMed ID: 30657361
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
    Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
    Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
    Carhill AA; Litofsky DR; Ross DS; Jonklaas J; Cooper DS; Brierley JD; Ladenson PW; Ain KB; Fein HG; Haugen BR; Magner J; Skarulis MC; Steward DL; Xing M; Maxon HR; Sherman SI
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3270-9. PubMed ID: 26171797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy?
    Zettinig G; Fueger BJ; Passler C; Kaserer K; Pirich C; Dudczak R; Niederle B
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):377-82. PubMed ID: 11940050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.
    Luo H; Tobey A; Auh S; Cochran C; Zemskova M; Reynolds J; Lima C; Burman K; Wartofsky L; Skarulis M; Kebebew E; Klubo-Gwiezdzinska J
    Clin Endocrinol (Oxf); 2018 Oct; 89(4):481-488. PubMed ID: 29972703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.